Graf Susan E 4

What Happened

• Susan E. Graf, a director of CG Oncology, was awarded a derivative equity grant covering 9,354 shares on 2026-06-04. The grant was reported as an award (transaction code A) at $0.00 per share — i.e., no cash was paid by the reporting person. This is an equity compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-04; reported on Form 4 filed 2026-06-05 (timely filing).
• Transaction type and amount: Grant/award of 9,354 shares (derivative security) at $0.00.
• Vesting: Footnote indicates 1/12th of the total shares vest monthly beginning June 4, 2026; if the next annual meeting occurs before the first anniversary, any remaining unvested portion will vest on that meeting date, subject to continued service.
• Shares owned after transaction: Not specified in the information provided.
• Filing timeliness: Filing appears timely (no late filing flag reported).

Context

• This was a compensation-related equity award to a director. Such grants are common for board compensation and represent future potential ownership as the award vests — they are not immediate purchases or sales of stock. Purchases by insiders can be stronger signals of conviction than routine awards; avoid inferring motivation from this grant alone.